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Background: Papillary thyroid carcinoma (PTC) is frequently accompanied by lymphocytic thy-
roiditis (LT). Some reports claim that Hashimoto’s thyroiditis (the clinical form of LT) enhances the 
likelihood of PTC; however, others suggest that LT has antitumor activity. This study was aimed 
to find out the relationship between the patterns of helper T cell (Th) cytokines in thyroid tissue of 
PTC with or without LT and the clinicopathological manifestation of PTC. Methods: Fresh surgical 
samples of PTC with (13 cases) or without (10 cases) LT were used. The prognostic parameters 
(tumor size, extra-thyroidal extension of PTC, and lymph node metastasis) were analyzed. The 
mRNA levels of two subtypes of Th cytokines, Th1 (tumor necrosis factor α [TNF-α], interferon γ 
[IFN-γ ], and interleukin [IL] 2) and Th2 (IL-4 and IL-10), were analyzed. Because most PTC cases 
were microcarcinomas and recent cases without clinical follow-up, negative or faint p27 immuno-
reactivity was used as a surrogate marker for lymph node metastasis. Results: PTC with LT cases 
showed significantly higher expression of TNF-α (p = .043), IFN-γ (p < .010), IL-4 (p = .015) than 
those without LT cases. Although the data were not statistically significant, all analyzed cytokines 
(except for IL-4) were highly expressed in the cases with higher expression of p27 surrogate 
marker. Conclusions: These results indicate that mixed Th1 (TNF-α, IFN-γ , and IL-2) and Th2 (IL-
10) immunity might play a role in the antitumor effect in terms of lymph node metastasis.
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▒ ORIGINAL ARTICLE ▒
The annual incidence of thyroid cancer is variable across the 
globe; for males, 1.2–2.6 per 100,000 and for females, 2.0–3.8 
per 100,000. The Unites States, Japan, Sweden, and France 
have higher than average incidence rates.1,2 In South Korea, the 
incidence of thyroid cancer is 0.88 per 100,000 in males and 
6.68 per 100,000 in females. Among thyroid cancers, papillary 
thyroid carcinoma (PTC) is the most common (83.8%).3 Hence, 
the etiology, prognosis, and pathophysiology of PTC have been 
investigated extensively in research studies. Current studies fo-
cus on the molecular pathology (such as the roles of E-cadherin, 
c-Met, and epidermal growth factor receptor) and genetic alter-
ations (such as RET/PTC, TRK, BRAF, and p53) of PTCs.4 
Most PTC cases are indolent and seldom behave aggressively, 
where aggressive behavior is characterized with frequent recur-
rences and metastases.5 Shibru et al.6 maintain that patients over 
the age of 45, with elevated expression levels of both cyclooxy-
genase 2 and vascular endothelial growth factor C, have a more 
aggressive PTC. Including this study, there have been many at-
tempts to find prognostic factors for PTC. For instance, Kebe-
bew et al.7 has recently found that BRAF mutations are signifi-
cantly associated with the aggressive behavior of thyroid cancer. 
There have been many attempts to develop therapeutic vac-
cines for cancer.8 Despite the many research studies on cancer 
immunotherapy, the role of immunity in the biological behavior 
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of PTC is still poorly understood. Among the limited data col-
lected on the influence of immunity on PTC behavior are find-
ings indicating an association between the immunity and the 
good prognosis in cases of PTC concomitant with Hashimoto’s 
thyroiditis (HT) or lymphocytic thyroiditis (LT).9,10
It is traditionally assumed that tumor growth is suppressed 
by T-helper 1 cell (Th1) immunity and supported by T-helper 
2 cell (Th2) immunity. However, even Th2 immunity can pro-
mote antitumor activity.11 Th1 immunity activates cytotoxic 
CD8+ T lymphocytes (CTLs). Although CTLs can acquire anti-
tumor immunity, some tumor cells escape CTL immune surveil-
lance and survive. Hence, from a practical point of view, Th1 
predominance in itself does not represent antitumor immunity. 
Th2 immunity provokes a humoral immune reaction, i.e., the an-
tibody-synthesizing immunity. While components of the Th2 
immunity, such as B cells and interleukin (IL) 10, make favorable 
conditions for tumor growth, tumor-infiltrating granulocyte-
linked Th2 immunity promotes antitumor activity.11
Although there are relatively few reports about Th immunity 
and PTC, one by Mardente et al.12 reported that a Th cytokine 
pattern from the peripheral blood of a patient with PTC with 
chronic LT has a predominantly Th2 immune reaction or mixed 
cell response. Intrathyroidal lymphocytes in HT are composed 
of both B cells and T cells, the majority of them are CD8+ T 
cells, which are cytotoxic to thyroid follicle cells.13 PTCs are of-
ten associated with chronic LT and HT; for instance, Shull et al.14 
demonstrated that diffuse LT is associated with PTC without 
therapeutic histories. In addition, Mauras et al.15 reported three 
cases of thyroid cancer with HT that did not have recurrent dis-
ease after a thyroidectomy. Therefore, it is difficult to determine 
which Th subtype immunity has superior antitumor activity 
over the other.
Several clinical trials have been conducted to induce cytotoxic 
immunity against thyroid cancers. Amino et al.16 used saline ho-
mogenates of thyroid tumors, and Gerfo et al.17 applied chemical-
ly altered thyroglobulins, but the clinical efficacy of these thera-
pies have not been proven yet. 
In the present work, we analyzed the pattern of Th immunity 
and investigated its relationship to the clinicopathological mani-
festation of PTC. With the current ease of early detection of 
PTCs, cases of advanced tumor stages are rare. Hence, we used a 
surrogate immunohistochemical marker, p27, to represent the 
possibility of lymph node metastasis, for it has been known that 
p27 expression is low in metastasizing PTC.18
MATERIALS AND METHODS
Case materials
After Institutional Review Board (IRB) approval (protocol No. 
08-0194), 23 patients from the Department of Pathology, Gang-
nam Severance Hospital, were enrolled in this study. The patients 
ranged in age from 35 to 59 years old, with a mean age of 47. 
Fresh surgical samples of PTC with (13 cases) or without (10 cas-
es) LT were collected from the records in the Department of Pa-
thology with the patients’ agreement and the formal permission 
of the IRB. The prognostic parameters (tumor size, extra-thy-
roidal extension of PTC, and lymph node metastasis) were ana-
lyzed. Among the subtypes of PTC samples in this group, 21 
were of the most conventional type and two cases were follicular 
variants. The fresh thyroid tissues were divided into PTC and 
nontumor portions and sampled separately. The nontumor por-
tions were used for measuring the mRNA quantities of the cy-
tokines, and the PTC portions were subject to immunohistochem-
ical staining of CIP1 (p21)/KIP1 (p27) for protein expression 
analysis, as described in more detail in later section.
Measurement of cytokine expression levels in the thyroid 
tissue
The nontumor portions of the patient samples were used to 
measure the mRNA levels of the following cytokines: tumor 
necrosis factor α (TNF-α), interferon γ (IFN-γ), IL-2, IL-4, IL-10, 
and IL-1β. The 13 cases with concomitant PTC and LT were re-
ferred to as the objective group, and the 10 cases of PTC without 
LT were used as a reference or control group. Quantitative real-
time polymerase chain reaction (PCR) was performed according 
to the manual of LightCycler 480 Real-Time PCR System (Roche 
Applied Science, Manheim, Germany).
The reference gene value (actin and 18S RNA) and IL-1β value 
were measured in every sample. Although it is known to be 
meaningless to compare the levels of cytokines from the same 
specimen, the expressed cytokine levels could be ranked and 
compared in this research via a quantitative real-time PCR meth-
od. Using the concept of relative quantification, the cytokine 
values were corrected for differences in quality and quantity by 
dividing the concentration of a target RNA by the concentration 
of a reference RNA in the same sample (relative ratio = concen-
tration of target/concentration of reference). The most common 
way to compare expression levels of different samples is to desig-
nate one of the samples as calibrator, where all other samples are 
compared to this calibrator. For normalization of the final re-
sults, the target/reference ratio of each sample is divided by the 
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target/reference ratio of the calibrator sample: calibrator normal-
ized ratio = (sample; concentration of target/concentration of refer-
ence)/(calibrator; concentration of target/concentration of refer-
ence).19 In the present work, we applied the constitutively-expressed 
cytokine, IL-1β, as the calibrator. There were cytokine values 
expressed as “not detected.” This means that the reference gene 
was calculated, but the target gene could not be detected de-
spite many PCR amplification processes. In these cases, we ad-
justed these “not detected” values to zero (0).
Immunohistochemistry 
The immunohistochemistry (IHC) of the p27 protein expres-
sion in the PTC tumor tissue from all 23 cases was analyzed us-
ing paraffin-embedded tissue. Formalin-fixed paraffin-embed-
ded sections (3 μm thick) were dewaxed in xylene and rehydrated 
through graded alcohols to water. Endogenous peroxidase activ-
ity was blocked in 3% hydrogen peroxide. Antigen retrieval was 
performed in citrate buffer (pH 6.0) within a microwave pressure 
cooker, and endogenous biotin detection was blocked with the 
Avidin-Biotin blocking kit (Vector Laboratories Inc., Burlin-
game, CA, USA).
Optimum primary antibody dilutions were predetermined, 
and appropriate positive control samples (tissues known to be 
positive for the immunohistochemical marker) and negative con-
trol samples (test tissue sections without the addition of primary 
antibody) were used for p27 (Novocastra, Newcastle upon Tyne, 
UK). The primary antibody incubation was diluted at 1:200 for 
1 hour. After incubation, the slide was washed with phosphate 
buffered saline, and a secondary incubation was carried out with 
biotin anti-mouse/anti-rabbit IgG followed by streptavidin-
HRP (Signet Pathology System, Dedham, MA, USA) for 30 
minutes. The immunoreaction was revealed by incubation in 
3-amino-9-ethylcarbazole. The slides were counterstained with 
hematoxylin and mounted in balsam.
When p27 immunoreaction was interpreted, only the nuclear 
staining on PTC cells was regarded as positive. Its measurement 
was evaluated by the following two-tiered grading system: low 
grade (negative staining or faint staining in less than 30% of the 
tumor cells) and high grade (positive staining in more than 30% 
of the tumor cells) (Fig. 1).20 Nuclear p27 immunoreactivity was 
considered altered when the expression was less than 30% of 
previously published, clinically relevant levels. In 21 cases, the 
results of IHC were summarized in two groups: the cases with LT 
(n = 13) and the cases without LT (n = 8). Two cases were not per-
formed, for the IHC sections for p27 were devoid of tumor tissue.
Statistical analysis
The Pearson chi-square test was used to examine the relation-
ships of cytokines (TNF-α, IFN-γ, IL-2, IL-4, IL-10, and IL-
1β) and p27 expression with the clinicopathological characteris-
tics. All reported p-values were 2-sided, and the significance was 
set at .05. All statistical tests were performed with SPSS ver. 17.0 
(SPSS Inc., Chicago, IL, USA).
RESULTS
Clinical manifestations and histopathological findings
PTC with LT (n = 13) 
The subtypes of the PTCs with LT were determined to be the 
A B
Fig. 1. p27 immunoreactivity (nuclear staining) on papillary thyroid carcinoma cells. Two-tiered grading system reveals a low grade (A, nega-
tive staining or faint staining less than 30% of tumor cells) and a high grade (B, positive staining more than 30% of tumor cells).
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most conventional (11/13, 84.61%), and those of only two cases 
were follicular variants (2/13, 15.38%). The tumor sizes ranged 
from 0.2 to 1.1 cm, with an average of 0.55 cm. Of the 13 cases 
of this type, six cases showed extrathyroidal tumor extension 
(ET) (6/13, 46.15%), and two cases presented with lymph node 
metastasis (2/13, 15.38 %). 
PTC without LT (n = 10) 
The subtypes of the PTCs with LT were all conventional 
(10/10, 100%). Three cases with ET were present (3/10, 30%). 
Tumor sizes ranged from 0.1 to 1.5 cm, with an average of 0.61 
cm. There were three cases with lymph node metastasis (3/10, 
30%).
Cytokine immune profiles
In all 23 cases, the cytokine immune profiles were summa-
rized into two groups: the cases with LT (n = 13) and the cases 
without LT (n = 10). The cytokines could have originated from 
inflammatory cells, thyroid tissue, and endothelial cells. In this 
research, the tissues were from the thyroid tissue near PTC.
PTC with LT (n = 13) 
After manipulating the data using the concept of a calibrator 
with IL-1β, each sample of PTC with LT was compared (Table 
1). Among the six cytokines analyzed, TNF-α, IL-4, and IFN-γ 
were relatively well expressed. Based on these factors, the cyto-
kine expression in the PTC samples with LT represented a 
mixed Th1 (TNF-α and IFN-γ) and Th2 (IL-4 and IL-10) im-
munity. 
PTC without LT (n = 10) 
After manipulating data using the concept of a calibrator 
with IL-1β, each sample of PTC without LT was compared (Ta-
ble 2). In contrast to the cases of PTC with LT, the cases without 
LT frequently exhibited nondetectable cytokine levels. Among 
the six cytokines analyzed, the expression levels of IFN-γ, IL-
Table 1. Cytokine and immune profiles of the cases with lymphocytic thyroiditis (n = 13)
Case No. TNF-α/IL-1β IL-4/IL-1β IFN-γ/IL-1β IL-10/IL-1β IL-2/IL-1β
1 81.28 47.94 11.15 0.14 0
2 4,130.98 3173.80 1163.73 0 0
3 3,328.36 2686.57 946.27 0 0
4 198.41 145.50 64.68 0.20 0
5 276.08 258.27 93.89 0.73 0.09
6 5,275.74 4,871.32 1,875.00 0 0
7 2,454.55 2,227.27 954.55 7.88 3.10
8 108.88 91.54 40.36 1.39 0.25
9 242.84 242.84 46.20 0.18 0
10 141.74 135.65 43.39 0.20 0.10
11 4.21 0.03 0.05 0.04 0
14 5.81 1.54 0.39 0.11 0.09
16 2.32 0 0.12 0.05 0
Median 198.41 145.5 46.2 0.16 0
TNF-α, tumor necrosis factor α; IL, interleukin; IFN-γ, interferon γ. 
Table 2. Cytokine and immune profiles of the cases without lymphocytic thyroiditis (n = 10)
Case No. TNF-α/IL-1β IL-4/IL-1β IFN-γ/IL-1β IL-10/IL-1β IL-2/IL-1β
12 5.67 0.18 0 0.13 0
13 3.41 0 0.09 0 0
15 28.04 16.16 0 0 0
17 11.93 1.05 0 0.36 0
18 43.76 0 0 0 0
19 62.07 22.07 0 1.71 0.25
20 5.06 0.08 0 0.10 0
22 512.61 277.47 5.21 0 0
23 8.19 2.56 1.66 0.02 0.03
25 32.47 0 0 2.18 0
Median 19.98 0.61 0 0.06 0
TNF-α, tumor necrosis factor α; IL, interleukin; IFN-γ, interferon γ.
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10, and IL-2 levels were too low to be measured. Based on these 
data, the cytokines expressed in PTC without LT represented a 
mixed Th1 (TNF-α) and Th2 (IL-4 and IL-1β) immunity.
Prognostic parameters according to the presence of LT
The prognostic parameters (tumor size, ET, and lymph node 
metastasis) were not statistically related to LT, but the cases with-
out LT had a tendency for lymph node metastasis (Table 3).
The cases with LT had enhanced expression of the cytokines 
(TNF-α, IFN-γ, IL-4, IL-10, and IL-2) compared to the samples 
of PTC without LT. Among the five cytokines, the expression 
levels of TNF-α, IFN-γ, and IL-4 were significantly higher in 
the cases with LT than in those without LT (p < .05).
In terms of p27 as a surrogate marker for lymph node metas-
tasis, the degree of p27 expression was not correlated with 
lymph node metastasis in this study; high-grade expression of 
p27 had a tendency to occur in PTC cases with LT. In contrast, 
lymph node metastasis occurred slightly more frequently in 
PTC cases without LT. Conclusively, the degree of p27 expres-
sion did not show any correlation with lymph node metastasis 
in this study (p = .15) (Table 4).
Cytokine immune profiles and clinical implications of the 
PTC cases with LT
Due to this unexpected finding, which revealed in the insuf-
ficiency of the PTC cases without LT to serve as a reference group, 
this study adopted a new goal to use the PTC cases with LT to 
analyze the relationship between cytokine immune profiles and 
prognostic parameters. In addition, the PTC cases in this study 
were mostly microcarcinomas, which might represent the in-
cipient phase of the tumors. The incipient phase of tumors must 
always have a limitation in representing proper tumor staging, 
such as tumor size, nodal metastasis, and tumor extension. Hence, 
in this study, p27 was used as a surrogate marker of lymph node 
metastasis in the cases of microcarcinoma (as an incipient carci-
noma).
Therefore, the statistical analysis of this profiles solely made 
use of the PTC cases with LT. Except for the IL-4 cytokine, the 
expression levels of the cytokines TNF-α, IFN-γ, and IL-10 
were lower in the cases with low-grade expression of p27 than 
those with high-grade expression of p27, but there was no sta-
tistical significance (Table 5). The cases with ET had a tendency 
to demonstrate higher levels of cytokine expression than those 
with intrathyroidal tumor confinement (Table 6). Again, there 
was no statistical significance.
In summary, although the data were not statistically signifi-
cant, the trends follow a pattern where higher cytokine levels were 
present in the cases with high grade expression of p27 (except for 
IL-4) and ET. 
DISCUSSION
This study revealed the presence of mixed Th1 (IFN-γ, TNF-α, 
and IL-2) and Th2 (IL-4 and IL-10) immunity in lymphocytes 
in cases of PTC with LT. 
Although there is no statistical significance with a limited case 
number, this study could infer some meaningful results.
Table 3. Relationship between clinical parameters and the cases with lymphocytic thyroiditis
Variable LT (n = 13) Non-LT (n = 10) p-value
Tumor size (cm) 0.50 (0.20–1.10) 0.50 (0.10–1.50) .707
Extrathyroidal extension 6 (46.15) 3 (30) .669
Lymph nodal metastasis 2 (15.38) 3 (30) .617
LG p27 (n = 14) 8/13 (61.53) 6/10 (60) .655
TNF-α 198.41 (2.32–5,275.74) 19.98 (3.41–512.61) .043
IL-4 145.50 (0–4,871.32) 0.61 (0–277.47) .015
IFN-γ 46.20 (0.05–1,875.00) 0 (0–5.21) < .001 
IL-10 0.14 (0–3.10) 0.06 (0–0.25) .508
IL-2 0 (0–3.10) 0 (0–0.25) .322
Values are presented as median (range) or number (%). 
The cytokine unit value is the ratio of each cytokine to IL-1β. 
LT, cases with lymphocytic thyroiditis; Non-LT, cases without lymphocytic thyroiditis; LG p27, low-grade expression of p27 immunohistochemistry; TNF-α, tu-
mor necrosis factor α; IL, interleukin; IFN-γ, interferon γ.
Table 4. Relationship between p27 immunopositivity and lymph 
nodal metastasis
Variable
Lymph nodal 
metastasis
(n = 5)
Without lymph 
nodal metastasis
(n = 18)
LG p27 (n = 14) 3/5 (60) 11/18 (61.11)
HG p27 (n = 7) 1/5 (20) 6/18 (33.33)
Values are presented as number (%).
LG p27, low-grade expression of p27 immunohistochemistry; HG p27, 
high-grade expression of p27 immunohistochemistry.
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In the cases with LT, the higher expression of cytokine levels 
had a tendency to be associated with high p27 immuno-reac-
tivity (Table 5). Furthermore, except for IL-4, all cytokines were 
decreased in the cases with LT and p27 underexpression, which 
represents the increased possibility of lymph node metastasis. 
Because IL-4 is associated with aggressive PTC, the fact that all 
cytokine except IL-4 were highly expressed in the cases with LT 
and increased p27 expression supports the hypothesis that high 
expression of cytokines except IL-4 may contribute to anticancer 
effect on the PTC in terms of lymph node metastasis.21
In contrast, the cases with ET revealed the higher expression of 
cytokines than those without ET. Based on these results, we pro-
pose that the higher expression of cytokines TNF-α, IFN-γ, IL-
2, and IL-1 might inhibit nodal metastasis but not inhibit (or 
possibly enhance) the extrathyroidal extension. In view of helper 
T cell immunity, mixed Th1 and Th2 immunity seems to play a 
role in anticancer activity by inhibiting lymph node metastasis.
There have been several studies on the immune profiles of thy-
roiditis. Among them, Phenekos et al.22 reported that HT and 
Graves’ disease have two different helper T cell immunities. In 
their report, with the preferential expression of IL-2, IFN-γ, IL-
12, and IL-18, a Th1 pattern of immune response which is char-
acteristic of cellular immunity, is dominant in HT. In contrast, 
Ajjan et al.23 reported a mixed Th1 and Th2 immune response in 
HT cases. They reported that reverse transcription polymerase 
chain reaction results showed both Th1 and Th2 immunity. 
The findings in our study corroborate these results.
Our findings demonstrated that IL-4 expression, together 
with other cytokines, has a tendency to be higher in the cases 
with ET. This may mean that IL-4 contributes to tumor exten-
sion. In contrast, in the cases with underexpression of p27, which 
may represent lymph node metastasis, IL-4 was higher than 
other cytokines. This may imply that IL-4 contributes to the lym-
phatic spread of the tumor, a concept that is supported by Vella 
et al.21 who demonstrated that IL-4 levels were augmented in 
aggressive PTCs. They suggested that PTC cells receive protec-
tion from apoptosis by IL-4 production in the activated T lym-
phocytes of thyroid glands. To determine which of these con-
flicting results in terms of both nodal metastasis and capsular 
tumor extension are correct, further study may be necessary to 
disclose the role of IL-4 in PTC biological behavior.
A previous work by Yip et al.24 demonstrated with in vitro 
tests that IL-1β was an anticancer factor, which suppressed the 
proliferation and reduced the invasive potential of human PTC 
cells. In this study, IL-1β was found to be constitutively expressed 
in all cases and was used as a calibrator to compare cytokine lev-
els among the cases. Unfortunately, due to its use as a calibrator 
in this study, IL-1β expression levels in each case could not be 
compared. 
It is generally accepted that there is a beneficial relationship 
between chronic LT and the biological behavior of PTC, which 
results in improved prognoses. Paulson et al.25 suggested that 
chronic LT might have a protective role in tumor spread. Sup-
porting this evidence, Mitsiades et al.26 reported that Th1 cyto-
kines, such as IFN-γ and TNF-α, increase the sensitivity of both 
normal and neoplastic thyrocytes to FasL and TRAIL, which 
lead to apoptosis. Furthermore, Ahn et al.27 established that HT 
was associated with PTC, as was chronic inflammation with can-
cer in other locations. They also mentioned that the coexistence 
of HT in PTC cases introduced favorable clinical outcomes 
compared with those of PTC without HT.27 Corroborating this 
idea, Yoon et al.28 determined that patients with PTC and chronic 
LT had smaller tumor sizes, a lower incidence of capsular inva-
sion, and a significantly lower incidence of lymph node metas-
tases compared to patients without chronic LT. Several studies 
have also indicated that antithyroid antibodies are able to rec-
ognize these malignant cells and destroy them in the same way 
that they destroy normal follicular cells, contributing to the low 
rate of clinical progression of these lesions.29,30
The p27 protein was first identified as an inhibitor of cyclin E/
Table 5. Relationship between p27 immunopositivity and the cytokine 
immune profiles in the cases with lymphocytic thyroiditis (n = 13)
Cytokine LG p27 (n = 8) HG p27 (n = 5) p-value
TNF-α 76.32 (2.32–4,130.98) 81.28 (5.81–5,275.74) .390
IL-4 53.85 (0–3,173.80) 47.94 (1.54–4,871.32) .313
IFN-γ 2.66 (0–1,163.73) 11.15 (0–1,875) .430
IL-10 0.07 (0–7.88) 0.11 (0–1.71) 1.000
IL-2 0 (0–3.10) 0 (0–0.25) .755
Values are presented as median (range). The cytokine unit value is the ratio 
of each cytokine to IL-1β. 
LG p27, low-grade expression of p27 immunohistochemistry; HG p27, 
high grade expression of p27 immunohistochemistry; TNF-α, tumor necro-
sis factor α; IL, interleukin; IFN-γ, interferon γ.
Table 6. Relationship between cytokine levels and tumor extension 
in the cases with lymphocytic thyroiditis (n = 13)
Cytokine ET (n = 6) IT (n = 7) p-value
TNF-α 43.54 (2.32–4,130) 28.04 (5.06–512.61) 1.000
IL-4 24.74 (0–3,173) 16.16 (0.08–277.47) 1.000
IFN-γ 5.77 (0.05–1,163.73) 0 (0–5.21) .153
IL-10 0.08 (0–7.88) 0 (0–0.10) .237
IL-2 0 (0–0.10) 0 (0) .376
Values are presented as median (range). The cytokine unit value is the ratio 
of each cytokine to IL-1β.
ET, extrathyroidal tumor extension; IT, intrathyroidal tumor confinement; 
TNF-α, tumor necrosis factor α; IL, interleukin; IFN-β, interferon β.
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CDK2 complexes during transforming growth factor β–induced 
G1 arrest.31 Phosphorylation is the mechanism primarily used 
for regulating p27 activity. The p27 protein possesses multiple 
tyrosine, serine, or threonine phosphorylation sites. The inhibi-
tory roles of p27 towards cyclin/CDK complexes are weakened 
by phosphorylation directed by certain signal transduction path-
ways.32 The current model delineates that p27 suppresses tu-
morigenesis by inhibiting cyclin/CDK activity in the nucleus, 
but it exerts other functions in the cytoplasm that are potentially 
oncogenic.33 
There have been several clinical studies describing the rela-
tionship between the expression of p27 and lymph node metasta-
sis. Karlidag et al.18 reported that p27 expression in nonmetas-
tasizing PTC was lower than that in normal thyroid tissue and 
higher than that in metastasizing PTC. 
Our IHC analysis showed that p27 expression did not dem-
onstrate any relationship to lymph node metastasis in PTC with 
LT, but this may be attributed to the early stage of the tumors, 
i.e., our study mainly included patients with microcarcinomas. 
There may be a chance that even PTC cases with low expression 
of p27 were too incipient to reveal lymph node metastasis. With 
this limitation in the evaluation of the relationship between cy-
tokine levels and nodal metastasis, the common p27 marker was 
used as a surrogate marker to represent the possibility of nodal 
metastasis in early phase PTCs. As aforementioned, after focus-
ing on the cases with LT, the cases with low-grade expression of 
p27 tended to be associated with lower levels of cytokines than 
those with high-grade expression of p27. This may implicate 
that the cases with lower levels of mixed Th1 and Th2 cytokines 
have a higher probability of having lymph node metastasis.
Considering the low cytokine expression in the cases with un-
derexpression of p27 (except for IL-4), our results indicate that 
mixed Th1 and Th2 immune cytokines have a tendency toward 
anticancer effects in terms of lymph node metastasis. To predict 
tumor prognosis from cytokine levels, further studies determin-
ing the absolute values and IHC of cytokines will be necessary.
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